SeaBridge Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-3,735
Closed -$207K 207
2025
Q3
$207K Buy
3,735
+200
+6% +$11.7K 0.03% 195
2025
Q2
$244K Buy
3,535
+600
+20% +$40.8K 0.05% 183
2025
Q1
$204K Hold
2,935
0.04% 194
2024
Q4
$252K Buy
+2,935
New +$317K 0.05% 184
2016
Q4
Sell
-42,690
Closed -$888K 261
2016
Q3
$888K Sell
42,690
-2,120
-5% -$52.6K 0.22% 109
2016
Q2
$1.21M Sell
44,810
-430
-1% -$11.8K 0.3% 99
2016
Q1
$1.23M Sell
45,240
-3,580
-7% -$95.9K 0.3% 96
2015
Q4
$1.42M Buy
48,820
+3,000
+7% +$83K 0.32% 92
2015
Q3
$1.24M Buy
45,820
+700
+2% +$19.8K 0.29% 95
2015
Q2
$1.24M Buy
45,120
+11,850
+36% +$333K 0.25% 87
2015
Q1
$888K Buy
33,270
+480
+1% +$11.1K 0.18% 99
2014
Q4
$694K Buy
32,790
+2,180
+7% +$48.7K 0.14% 110
2014
Q3
$729K Sell
30,610
-12,060
-28% -$278K 0.17% 102
2014
Q2
$985K Buy
42,670
+34,820
+444% +$769K 0.2% 98
2014
Q1
$179K Hold
7,850
0.04% 130
2013
Q4
$145K Hold
7,850
0.03% 144
2013
Q3
$133K Buy
7,850
+850
+12% +$14.3K 0.03% 145
2013
Q2
$108K Buy
+7,000
New +$117K 0.03% 145

Other funds holding NVO

SeaBridge Investment Advisors's NVO Position: Q4 2025 in Review

SeaBridge Investment Advisors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 3,735 shares — an estimated $207K sold.

SeaBridge Investment Advisors first reported a position in NVO in Q2 2013 and held it in 18 quarters. The position peaked at $1.42M in Q4 2015. 1,416 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • SeaBridge Investment Advisors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • SeaBridge Investment Advisors sold 3,735 Novo Nordisk shares in Q4 2025, an estimated $207K.
  • SeaBridge Investment Advisors first reported a position in Novo Nordisk in Q2 2013 and held it in 18 quarters.
  • SeaBridge Investment Advisors's Novo Nordisk position peaked at $1.42M in Q4 2015.
  • 1,416 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on SeaBridge Investment Advisors's 13F filing for Q4 2025, filed 26 Jan 2026.